



IBA Launches the New Global Quality Assurance Platform **myQA™** - Connecting People, Know-how, and Dosimetry Applications

The uniquely designed software platform for Quality Assurance (QA) applications provides simple, consistent and efficient QA solution.

Austin, TX, July 17th, 2014 – IBA (Ion Beam Applications S.A.), the global high-tech leader in the next generation of proton therapy solutions and radiation therapy dosimetry for the treatment of cancer, announces the launch of a unique software platform for quality assurance, called **myQA**. This announcement is made at the annual congress of the American Association of Physics in Medicine (AAPM).

This software platform sets a new workflow efficiency standard by integrating all QA needs under one software roof, connecting plan verification, machine QA and commissioning; all of which is accessible via a single Cockpit application. The applications are developed from scratch which results in an easy, consistent and efficient all-in-one QA software platform. The Cockpit provides a swift and complete overview from the radiation therapy department, showing the status of the different QA applications. Using various devices, including smartphones and tablets, the Cockpit is able to provide an instant update of the complete QA status of the department.

myQA not only connects dosimetry applications, but people as well. By connecting users with the global know-how, research, and training in dosimetry, the new software platform addresses needs in the rapidly evolving radiation therapy environment. Based on the network's experience and best practice, new treatment methods can be applied faster and with more confidence which results in safer patient treatments. Moreover, the software platform connects dosimetry applications through a central database on a server, or if desired, via the cloud. This enables physicists and dosimetrists to implement the most efficient QA workflow for their department, and also for their satellite and partner hospitals. All patients, QA projects, and equipment data are stored on the central database resulting in increased data safety and integrity.

"For the last six months I have been using the new IMRT + plan verification software module which is part of myQA. The entire software package has been completely redesigned and re-engineered from the ground up to maximize efficiency and streamline the QA processes", says James P. Nunn, MS, CHP, DABR, Senior Medical Physicist at Lewis Gale Regional Cancer Center, Pulaski, USA. "I am excited about the possibility of IBA releasing more QA modules around the plan verification I am already using. Having the ability to interface with various software solutions and to keep track of my entire machine and patient QA on a central cockpit will enable me to have full control of the QA status within our department and sister center without missing crucial information. Most important for me is the ability to connect with my peers through myQA, which will be key for me to ensure better and more efficient QA."

*"Today we are excited and proud to unveil **myQA**, our new global software platform. We have carefully taken into consideration the voice of our users around the world in order to understand their daily challenges, needs and dreams", remarked Ralf Schira, Vice President of Marketing for IBA Dosimetry. "Having fast and efficient access to information and data becomes more and more crucial in the rapidly changing environment of radiation therapy. Being connected to other users with similar challenges, to share best practice, and to commonly find solutions is becoming a critical success and safety factor in dosimetry. We are convinced that **myQA** will fulfill our users' needs in providing safer treatments in a more efficient and comprehensive way. With this launch the journey has just begun!"*

Press Release |



Key dosimetry applications for patient plan verification, machine QA, as well as an interface to beam scanning and commissioning applications, will be available with the first release of **myQA**.

About IBA

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company. IBA is the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today. The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centres as well as next generation compact, single room systems.

IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety, as well as particle accelerators for medical and industrial applications.

Headquartered in Belgium and employing more than 1,000 people worldwide, IBA currently has installed systems across Europe, and the USA and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors by providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com.

Media Contact:

Ralf Schira
IBA Dosimetry GmbH
Bahnhofstr. 5
90592 Schwarzenbruck, Germany
Tel.: +49 9128 607 0
ralf.schira@iba-group.com